Core Viewpoint - The animal health sector experienced a significant increase of 3.8% on January 5, with Haili Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1] - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1] Group 2: Individual Stock Performance - Haili Biological (603718) closed at 6.58, with a rise of 7.87% and a trading volume of 461,200 shares, amounting to a transaction value of 302 million yuan [1] - Biological Shares (600201) closed at 16.06, increasing by 6.57% with a trading volume of 553,300 shares, totaling 88.5 million yuan [1] - ST Green Health (002868) closed at 35.40, up by 5.01% with a trading volume of 14,600 shares, amounting to 5.124 million yuan [1] - Shunlian Biological (688098) closed at 9.29, increasing by 4.62% with a trading volume of 65,000 shares, totaling 60.117 million yuan [1] - Ruipu Biological (300119) closed at 19.53, up by 4.05% with a trading volume of 78,500 shares, amounting to 151 million yuan [1] - KQ Biological (688526) closed at 15.68, increasing by 2.75% with a trading volume of 29,900 shares, totaling 46.631 million yuan [1] - Huisheng Biological (300871) closed at 21.25, up by 2.51% with a trading volume of 61,500 shares, amounting to 129 million yuan [1] - Qudongli (920275) closed at 8.91, increasing by 2.30% with a trading volume of 10,300 shares, totaling 911,930 yuan [1] - Placo (603566) closed at 12.71, up by 2.25% with a trading volume of 36,700 shares, amounting to 46.3405 million yuan [1] - Jinhai Biological (002688) closed at 6.03, increasing by 1.34% with a trading volume of 105,100 shares, totaling 63.2745 million yuan [1] Group 3: Capital Flow Analysis - The animal health sector saw a net inflow of 77.0149 million yuan from main funds, while retail funds experienced a net outflow of 33.0955 million yuan [1] - The main funds' net inflow for Haili Biological was -54.2922 million yuan, with a net outflow from retail funds of -35.0631 million yuan [2] - Ruipu Biological had a net inflow of 15.0755 million yuan from main funds, while retail funds saw a net inflow of 555.73 thousand yuan [2] - Biological Shares had a net inflow of 1.5843 million yuan from main funds, with a net outflow from retail funds of -1529.42 thousand yuan [2]

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]

证券日报网讯 12月30日，金河生物（002688）发布公告称，公司拟为全资子公司金河环保向建设银行 呼和浩特分行申请的10，000万元固定资产贷款提供连带责任保证担保，用于污水处理厂扩容及水资源 再生利用提标扩建工程。截至公告披露日，公司及子公司累计对外担保余额为46，305.34万元，占公司 2024年经审计归属于母公司所有者净资产的20.61%，不存在逾期担保。 ...

Group 1 - The company announced that it will provide a guarantee for its wholly-owned subsidiary, Inner Mongolia Jinhai Environmental Technology Co., Ltd., to secure a loan of up to 100 million RMB from China Construction Bank for a wastewater treatment plant expansion project [1] - The loan is intended for a five-year term with an interest rate based on the current LPR rate, specifically for the project aimed at enhancing wastewater treatment capacity and water resource recycling [1] - As of the announcement date, the total external guarantee balance for the company and its subsidiaries is approximately 463 million RMB, which includes the new guarantee and represents 20.61% of the audited net assets attributable to the parent company for 2024 [1] Group 2 - The new guarantee amount of 100 million RMB will account for 4.45% of the audited net assets attributable to the parent company for 2024 [1] - The guarantee requires approval from the company's shareholders through a special resolution and does not involve related party transactions or require approval from relevant authorities [1]

Group 1 - The company Jinhe Biological announced the approval of several proposals during the 35th meeting of its sixth board of directors, including the repurchase and cancellation of certain restricted stocks [2] - The company plans to change its registered capital and amend certain clauses as part of its strategic initiatives [2] - A temporary shareholders' meeting is scheduled for January 16, 2026, to discuss these matters [2]

格隆汇12月30日丨金河生物(002688.SZ)公布，第六届董事会第三十五次会议，以9票同意，0票反对，0 票弃权审议通过了《关于对外投资设立全资子公司的议案》，同意公司以自有或自筹资金投资5,000万 元于内蒙古金河东汇生物科技有限公司。（最终以市场监督管理局核定名称为准）。 ...

Core Viewpoint - On December 30, Jinhe Biology announced the approval of an investment to establish a wholly-owned subsidiary, indicating a strategic move to expand its business operations [1] Group 1: Company Actions - The company held its 35th meeting of the sixth board of directors to discuss and approve the investment proposal [1] - Jinhe Biology plans to invest 50 million yuan in Inner Mongolia Jinhe Donghui Biotechnology Co., Ltd. using its own or raised funds [1]

Core Viewpoint - The company has decided to conclude a fundraising project and permanently supplement its working capital with the remaining funds due to the completion of the project and the need for efficient use of raised funds [1] Group 1: Project Conclusion - The company held its 35th meeting of the 6th Board of Directors on December 30, 2025, where it approved the conclusion of the "Production Process System Energy Saving and Efficiency Improvement Project" [1] - The project had a committed investment amount of 55.6113 million yuan, with a total of 53.5566 million yuan invested as of December 25, 2025 [1] - The remaining funds amount to 2.3277 million yuan, primarily due to some supplier payments and warranty funds not meeting the contractual payment conditions [1] Group 2: Fund Allocation - The company plans to use the remaining funds to permanently supplement its working capital, which will lead to the cancellation of the corresponding fundraising special account and the termination of related regulatory agreements [1]

Core Viewpoint - The company announced a plan to repurchase and cancel a portion of restricted stock due to the death of one of the incentive plan participants, which affects the overall stock structure [1] Group 1: Stock Repurchase Details - The company will repurchase and cancel a total of 30,000 shares of restricted stock, which represents 0.0039% of the company's total share capital before the repurchase [1] - The repurchase price is set at 2.29 yuan per share, plus the interest from the People's Bank of China for the same period, leading to a total repurchase amount of 68,700 yuan including interest [1] - The funding for this repurchase will come from the company's own funds [1] Group 2: Corporate Governance - The decision to repurchase the shares was made during the 35th meeting of the sixth board of directors held on December 30, 2025 [1] - This matter will be submitted for review at the company's first extraordinary shareholders' meeting in 2026 [1]

Core Viewpoint - The company plans to invest 50 million yuan to establish a wholly-owned subsidiary in Hohhot, Inner Mongolia, aimed at enhancing production capacity and resource allocation in the veterinary medicine and feed additive sectors [1] Group 1: Investment Details - The registered capital of the new subsidiary will be 50 million yuan, with a 100% ownership stake by the company [1] - The investment is intended to leverage the advantages of the company's Phase VI project and improve cost management and operational efficiency [1] Group 2: Strategic Alignment - This initiative aligns with the company's overall development strategy and aims to expand its business layout in veterinary medicine and feed additives [1] - The establishment of the subsidiary does not require shareholder approval and is not classified as a related party transaction or a major asset restructuring [1] Group 3: Risk Management - The new subsidiary is subject to the completion of business registration, which carries certain market and operational risks [1] - The company will enhance internal controls and risk prevention mechanisms to mitigate potential risks [1]